
Opinion|Videos|January 22, 2025
Safety Profile of Second-Line Agent in Patients With Compensated Cirrhosis
Panelists discuss how the safety profiles of second-line primary biliary cholangitis (PBC) therapies in compensated cirrhosis show varying levels of risk, with recent abstracts from EASL and AASLD 2024.
Advertisement
Episodes in this series

Video content above is prompted by the following:
- How do the safety profiles of seladelpar, elafibranor, and obeticholic acid impact their use in patients with compensated cirrhosis?
- Include in your discussion the EASL 2024 abstract.
- Include in your discussion the EASL 2024 abstract.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
TrumpRx Launches, Offering Cash-Paying Patients Discounted Drugs
2
SGLT2 Inhibitors in T2D Lower 5-Year Risk of CKD and Acute Kidney Injury
3
Pharmacist Takeover: CAR T Therapy Signals a Shift in ALL Treatment
4
Balancing Survival and Quality of Life in Pancreatic Cancer: Expert Perspectives From an Immuneering Panel
5

























